酒石酸托特罗定治疗膀胱过度活动症的临床研究

目的探讨酒石酸托特罗定在治疗膀胱过度活动症（OAB）中的临床疗效及安全性。方法60例OAB患者随机分为试验组（n=30）和对照组（n=30）：试验组口服酒石酸托特罗定片（2mg／片）1片，2次／d，42d为1个疗程；对照组口服非那雄胺，5mg，1次／d，坦索罗辛缓释胶囊，0．2g，1次／d，42d为1个疗程。两组治疗前后均记录排尿情况，进行OAB症状评分（OABSS评分），测定最大尿流率（Qmax）。结果与治疗前比较，试验组治疗后排尿次数、尿急次数、夜尿次数、急迫性尿失禁次数均明显减少，每次排尿量明显增加。试验组治疗后排尿次数、尿急次数、夜尿次数、急迫性尿失禁次数均明显少于对照组，每次排尿量明显多于对照组。试验组治疗后OABSS评分明显低于治疗前；试验组治疗后OABSS评分明显低于对照组治疗后。试验组不良反应次数明显低于对照组。结论酒石酸托特罗定是治疗OAB的理想药物。

Clinical Study of Tolterodine Tartrate in the Treatment of Overactive Bladder

Objective To explore the clinical therapeutic effect and safety of Tolterodine Tartrate in the treatment of overactive bladder （OAB）. Methods Sixty patients with OAB were randomly divided into experimental group （n=30） orally administrated one tablet of Tolterodine Tartrate （2 mg/tablet） and control group （n=30） orally given Finasteride, 5 mg, QD; Tan solo sustained-release capsules, 0.2 g, QD, 42 d as one course. Urination and OABSS were recorded and Qmax were examined before and after treatment. Results The frequencies of urination, urgent urination, nocturia and urge incontinence in experimental group decreased obviously with increased voided volume each time, compared with the treatment before and with those in control group. Additionally, the OABSS and adverse reaction were evidently lower in experimental group after treatment than those in control group. Conclusion Tolterodine Tartrate is an ideal medicine in treating OAB.